rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Inhibikase Therapeutics, Inc.

IKT · Nasdaq

Health CareBiotechnologyNot moving yet

IKT stood above a rising 150-day average in 22 of the last 52 weekly readings, and has been out of that trend for the last 3 weeks. It is 14.4% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−14 points in four weeks); Health Care: 28% (−9 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 3
Industry in uptrend
18% -14 in 4 wk
Insider buys, 12 months
$3.0M
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
106 (+7)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 22 of 52 weeks.

21 Apr – 20 Oct
18%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$2.9MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months1
Sale orders, 12 months0
Buyers · sellers1 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders106+7 on the quarter
New · exited21 · 14
Reported value$241.1M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Sands Capital Alternatives, LLCunchanged · filed 13 Aug 202613,018,965$26.4M00.0%
Soleus Capital Management, L.P.unchanged · filed 11 Aug 202610,875,000$22.1M00.0%
Trails Edge Capital Partners, LPadded · filed 14 Aug 20269,051,318$18.4M+993,973+12.3%
Fairmount Funds Management LLCunchanged · filed 14 Aug 20268,625,000$17.5M00.0%
BlackRock, Inc.added · filed 7 Aug 20267,768,057$15.8M+1,464,624+23.2%
ADAR1 Capital Management, LLCadded · filed 14 Aug 20267,387,205$15.0M+780,633+11.8%
Blackstone Inc.unchanged · filed 14 Aug 20265,938,276$12.1M00.0%
Siren, L.L.C.unchanged · filed 13 Aug 20265,850,000$11.9M00.0%
Commodore Capital LPunchanged · filed 14 Aug 20265,397,488$11.0M00.0%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20264,935,354$10.0M+484,689+10.9%
30 Jun 2023 – 30 Jun 2026
1358103Jun 23Mar 24Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Dennis N. Berman Company insiderDirector · last 30 Jul 20260 · 0
Ra Capital Healthcare Fund Lp Company insider10% owner · last 29 Jul 20260 · 0
RA CAPITAL MANAGEMENT, L.P. Company insider10% owner · last 29 Jul 20260 · 0
Amit Munshi Company insiderDirector · last 26 Jun 20261 · 0
Arvind Kush Company insiderDirector · last 26 Jun 20261 · 0
David Canner Company insiderDirector · last 26 Jun 20260 · 0
Roberto Bellini Company insiderDirector · last 26 Jun 20261 · 0
Vincent Aurentz Company insiderDirector · last 26 Jun 20260 · 0
Christopher Cabell Company insiderPresident & Head of R&D · last 21 Feb 20260 · 0
David McIntyre Company insiderChief Financial Officer · last 5 Jan 20260 · 0
Mark T. Iwicki Company insiderChief Executive Officer · last 5 Jan 20260 · 0
Frank M. Sands Company insider10% owner · last 21 Nov 20251 · 0

Same industry

MRNA ModernaLeading+167%
ENTX Entera BioLeading+52%
XNCR XencorLeading+41%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-30.1%
Interest coverFY 2025 · to 31 Dec 2025-13.99×
Share count trendFY 2025 · to 20 Mar 20260.3%
Cash and equivalentsFY 2025 · to 31 Dec 2025$178.8M
Free cash flowFY 2025 · to 31 Dec 2025−$27.8M

Analyst forecasts

No analyst forecasts yet.